Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: A case report and review of the literature

Sikander Ailawadhi, Shenoy Sadashiv, Sham Ronald, Javle Milind

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.

Original languageEnglish (US)
Pages (from-to)638-639
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Portal Vein
Hepatocellular Carcinoma
Thrombosis
Incidence
Neoplasms

Keywords

  • Chemoembolization
  • Hepatocellular carcinoma
  • Portal vein thrombosis

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

@article{657484a7b297441fba864f76e31bece3,
title = "Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: A case report and review of the literature",
abstract = "Primary hepatocellular carcinoma (HCC) accounts for more than 5{\%} of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8{\%}. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.",
keywords = "Chemoembolization, Hepatocellular carcinoma, Portal vein thrombosis",
author = "Sikander Ailawadhi and Shenoy Sadashiv and Sham Ronald and Javle Milind",
year = "2005",
month = "12",
doi = "10.1097/01.coc.0000158488.36371.50",
language = "English (US)",
volume = "28",
pages = "638--639",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis

T2 - A case report and review of the literature

AU - Ailawadhi, Sikander

AU - Sadashiv, Shenoy

AU - Ronald, Sham

AU - Milind, Javle

PY - 2005/12

Y1 - 2005/12

N2 - Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.

AB - Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.

KW - Chemoembolization

KW - Hepatocellular carcinoma

KW - Portal vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=29044433658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044433658&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000158488.36371.50

DO - 10.1097/01.coc.0000158488.36371.50

M3 - Review article

C2 - 16317281

AN - SCOPUS:29044433658

VL - 28

SP - 638

EP - 639

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 6

ER -